On December 7, according to the official website of CDE, the clinical trial application of Innovent Biologics' Class 1 new drug IBI3002 was accepted. According to public information, IBI3002 is a FIC bispecific antibody targeting IL-4Rα and TSLP.

Asthma is a heterogeneous disease mediated by a variety of immune cells, cytokines and inflammatory mediators, affecting people of all ages, characterized by a variety of symptoms such as wheezing, shortness of breath, cough and chest tightness, with hundreds of millions of patients worldwide. Drug treatment is one of the important means to relieve and control asthma.

The IL-4 receptor mediates the IL-4 signaling pathway (type 1 and type 2) and the IL-13 signaling pathway (type 2), and both cytokine signaling pathways play a key role in the pathophysiology of type 2 inflammatory diseases. TSLP is an epithelial cell-derived alarmin cytokine that triggers type 2 and non-type 2 inflammation in asthma.

According to Innovent Biologics, IBI3002 has a highly efficient co-blocking function of IL-4Rα and TSLP, and in vitro functional experiments show that it is superior to the marketed monoclonal antibodies with the same target. By simultaneously targeting IL-4Rα and TSLP, IBI3002 has the potential to inhibit type 2 and non-type 2 inflammation, has potential synergistic effects in inhibiting type 2 inflammation, and is expected to show superiority in the treatment of type 2 inflammatory diseases.

Previously, Innovent Biologics registered a clinical study of IBI3002 on the clinicaltrials official website for patients with asthma. In March of this year, Innovent Biologics announced that the first human clinical phase I study of IBI3002 had completed the first subject administration in Australia.

The clinical trial application of IBI3002 was successfully approved. Innovent Biologics may start further research on it in China, which is expected to bring new options to asthma patients.

https://news.yaozh.com/archive/44657.html